MichaelGlenKauffmanMDPhD

PubMed

• 118 citations
  Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
  Dan T. Vogl, David Dingli, Robert F. Cornell, Carol Ann Huff, Sundar Jagannath
  Journal of Clinical Oncology. 2018-01-30
• 128 citations
  Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.
  Jessica Schmidt, Esteban Braggio, Klaus Martin Kortuem, Jan B. Egan, Yuanxiao Zhu
  Leukemia. 2013-06-11
• 41 citations
  Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor
  Shaun Rosebeck, Mattina Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum
  Molecular Cancer Therapeutics. 2016-01-01

Abstracts/Posters

• Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018